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Purpose: To develop chitosan/alginate microparticles for the mucosal delivery of allergen from dust mite 
(Dermatophagoides pteronyssinus).  
Methods: Chitosan/alginate microparticles were prepared by ionotropic gelation. The effects of polymer 
content, crosslinking agent, and preparation method on the physicochemical characteristics of the 
microparticles as well as their in vitro cytotoxicity were investigated.  
Results:  The microparticles were small (1 - 17 µm) and spherical in shape. The highest allergen 
content (0.30 ± 0.07 mg/g) was obtained with 2.5 % initial allergen loading in chitosan- triphosphate 
(CS-TPP) microparticles. Sustained allergen release  (approx. 50 % over 24 h) was observed from 
alginate-coated chitosan microparticles. Allergen incorporation method and initial drug-loading could be 
varied to obtain optimum particle size with high allergen-loading and sustained release. The cytotoxicity 
of various microparticle formulations did not differ significantly (p > 0.05 ), as cell viability values were 
close to 100 %.  
Conclusion:  This study indicates that alginate and alginate-coated chitosan microparticles are safe 
and can be further developed for mucosal allergen delivery.  
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INTRODUCTION 
 
Chitosan, as a cationic polysaccharide, has 
gained increasing attention in pharmaceutical 
research and development due to its 
favorable biological properties, such as non-
toxicity, biodegradability and mucoadhesive 
properties. Additionally, chitosan 
micro/nanoparticles can be easily prepared 
by ionic gelation method using 
tripolyphosphate (TPP) as precipitating agent 
[1,2]. In spite of its unique properties, 
chitosan has an apparent pKa of 5.6 - 6.2 
and is only soluble in acidic solutions. When 
incubated in physiological fluid environment, 
chitosan loses its mucoadhesive capacity and 
permeation enhancing effect due to 
deprotonation of chitosan, which causes 
chitosan to lose its advantage over other 
carriers for mucosal vaccine delivery.  
 
However, chitosan has limited ability for 
controlling release in acid medium [3]. One 
approach to overcome this and other 
obstacles is by coating an acid-resistant 
polymer, such as sodium alginate, onto the 
surface of chitosan microparticles [4]. 
Usually, chitosan–alginate microparticles are 
obtained by two principally different 
procedures. The first is a one-step method, 
where a complex coacervate membrane is 
formed at the interface between the alginate 
and chitosan solutions when the alginate 
solution is dropped directly into a solution of 
calcium chloride mixed with chitosan, while 
the other method is a two-step method, 
where chitosan-TPP microparticles are 
recovered and subsequently coated with 
calcium alginate.  
 
Recently, we successfully prepared bovine 
serum albumin (BSA)-loaded alginate 
microparticles by crosslinking alginate with 
calcium chloride solution using an 
electrohydrodynamic spraying technique [5]. 
The advantage of this method was attributed 
to the mild condition, which excluded the 
application of harmful organic solvent, at 
room temperature, and also efficiently 
retained the bioactivity of macromolecules 
(protein, DNA, etc) during encapsulation. The 
main objective of this study, therefore, was to 
prepare a microparticulate system (coated 
with sodium alginate and incorporating dust 
mite allergen) by cross-linking alginate with 
calcium, and chitosan with TPP, and 
characterize them for their release and other 






High viscosity sodium alginate, derived from 
brown algae  (AHV, 40000 cps) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) were purchased from Sigma-
Chemical Co., St. Louis, MO, USA. Chitosan 
(mol wt: 20, 200 and 460 KDa) was 
purchased from Seafresh Chitosan Lab 
Bangkok, Thailand). Allergenic extract 
standard mite (dust mite allergen, Ag) was 
obtained from ALK-Abelló, Inc., Round Rock, 
TX, USA. Penta-sodium triphosphate (TPP) 
was purchased from Ajax Chemicals, New 
South Wales, Australia. Caco-2 cells were 
obtained from American Type Culture 
Collection (Rockville, MD,USA). Dulbecco’s 
modified Eagle’s medium (DMEM), trypsin-
EDTA, penicillin-streptomycin antibiotics and 
fetal bovine serum (FBS) were supplied by 
Gibco-Invitrogen, Grand Island, NY, USA.  
 
Preparation of chitosan salt (CS) 
 
Chitosan hydrochloride salt (CS) was 
prepared as previously described [1].  Briefly, 
1 %w/w CS solution was prepared by 
dissolving chitosan in distilled water 
containing hydrochloric acid in a 1:0.8 molar 
ratio and then stirred for 12 h at room 
temperature.  The solution (10 ml) was spray-
dried (Minispray Dryer, Büchi 190, Postfach, 
Switzerland) at an inlet temperature of 125 ± 
2 
0
C at spraying rate of 8 ml/min. 
Preparation of alginate-coated, allergen-
loaded chitosan microparticles  
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Chitosan microparticles were prepared by 
ionotropic gelation [1]. Briefly, CS and TPP 
were dissolved in water with magnetic stirring 
to prepare solutions of 0.1% w/v CS and 0.2 % 
w/v TPP. Allergen-loaded chitosan micro-
particles (Ag-CS-TPP) were prepared by 
drop-wise addition of 10 ml TPP solution 
containing dust mite allergen (0.1, 0.5, 2.5 
%w/v) into a 40 ml CS solution while stirring 
at 700 rpm for 20 min. The resultant particles 
were collected, washed with distilled water 
and separated by centrifugation at 3000 rpm 
for 15 min. They were then lyophilized 
(Labconco, Freezone 2.5, Kansas City, MO, 
USA) and stored at 4 °C. Blank CS-TPP 
microparticles (without allergen) were 
similarly prepared. 
 
To prepare alginate-coated microparticles 
(Ag-CS-TPP), 2.5 % of allergen (Ag)-CS-TPP 
microparticles were selected. Briefly, the 
powders (sodium alginate and CaCl2) were 
dissolved separately in water using a 
magnetic stirred to obtain solutions of 0.025, 
0.05, 0.1, 0.25, 0.5 %w/v and CaCl2 (4 or 6 % 
w/v), respectively. Fifty microliters of the 
alginate solution were mixed well with 13 mg 
of CS-TPP microparticles and extruded 
dropwise by electrohydrodynamic spraying 
techniques as previously described [5] 
through a glass syringe fitted with a 20-gauge 
blunt needle into 150 mL of 4 or 6 %w/v 
CaCl2 solution under gentle stirring. This 
setup used the applied voltage for 18 kV  
(Protek
®
 DC power supply) with the distance 
from the needle tip to the receptor solution 
(CaCl2) and extrusion rate fixed at 30 cm and 
1 ml/h, respectively. After extrusion, the 
microparticles were collected in CaCl2 with 
gentle stirring for 30 min, separated from the 
CaCl2 solution by centrifugation at 5862 g for 
10 min, washed twice and re-suspended in 
distilled water. This suspension was 
lyophilized and then stored at 4 °C. Blank 
microspheres (without allergen) were 
similarly prepared. 
 
Morphology and particle size distribution 
 
Morphological characterization of the 
microparticles was performed by inverted 
microscopy (Eclipse TE 2000-U, Japan) at a 
magnification of x 20 as well as by 
transmission electron microscope (Jeol 
Jem1230, Tokyo, Japan). Particle size 
analysis was measured using Zetasizer Nano 
ZS (Malvern Instruments, Malvern, UK).  
 
Reverse-phase HPLC analysis of allergen 
 
The reverse-phase high performance liquid 
chromatography (HPLC) system for the 
determination of allergen consisted of an 
Agilent HPLC system (Agilent 1100 series, 
USA) at a flow rate of 1.0 ml/min. For 
separation, a C18 reverse-phase column (5 
µm, 150 mm x 0.5 mm, Waters, USA) was 
used. The following gradient elution profiles 
were used: solvent A, 0.1%v/v trifluoroacetic 
acid (TFA) in water; and solvent B, 0.085 
%v/v TFA in acetonitrile [6].  The injection 
volume was 20 µl. The detection was 
performed using a fluorescence detector with 
an excitation wavelength of 280 nm and 
emission wavelength of 304 nm. 
 
Determination of allergen (Ag) entrapment 
efficiency 
 
One hundred milligrams of Ag-CS-TPP 
microparticles were dissolved in 2 ml of 5M 
HCl (pH 1.2) while the same amount of 
alginate-coated Ag-CS-TPP microparticles 
was dissolved in phosphate buffer saline 
(PBS, pH 7.4). The mixture, in each case, 
was stirred at room temperature until 
completely dissolved. The amount of allergen 
in the microparticles was determined by a 
reverse-phase HPLC. The yield, entrapment 
efficiency (EE), and loading capacity (LC) 
were calculated as in Eqs 1 - 3, respectively 
[7]. 
Yield (%) = (Wm/Wt ) x 100 ………… (1) 
where Wm is the weight of microparticles and 
Wt is the theoretical weight of microparticles.  
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EE  =  (Pt/ Lt) x 100  ……………..……. (2) 
 
where Pt is the amount of allergen embedded 
in microparticles. Lt is the theoretical amount 
of allergen (obtained from feeding condition) 
incorporated into microparticles.  
 
LC =  Pt/Mt ……………………………… (3) 
 
where Pt is the amount of allergen embedded 
in microparticles (in mg), and Mt is the total 
amount of microparticles harvested (in g). 
 
Assessment of in vitro allergen release  
 
In vitro release studies were performed by 
suspending 10 mg of microparticles in 1.5 ml 
microcentrifuge tubes with 1 ml of PBS pH 
7.4 or simulated gastric fluid without pepsin 
(0.2% w/v NaCl and 0.7% v/v HCl) pepsin 
(pH 1.2). All the tubes were then incubated at 
37 °C in a shaker-incubator shaking at 200 
rpm to maintain the particles in suspension 
(sink conditions). To determine the amount of 
allergen released after a given time (1, 2, 4, 
8, 12 and 24 h), the sample was centrifuged 
for 15 min at 1077 x g. The supernatant was 
measured in triplicate by reverse-phase 
HPLC using fluorescence detector at an 
excitation wavelength of 280 nm and 




The colonic adenocarcinoma cell line, Caco 2 
cells, were grown in Dulbecco's modified 
Eagle's medium (DMEM) at pH 7.4, 
supplemented with 10 % fetal bovine serum, 
2 mM L-glutamine, 1 % non-essential amino 
acid solution and 0.1 % penicillin-
streptomycin solution in a humidified 
atmosphere (5 % CO2, 95 % air, 37 °C). The 
cells were grown under standard conditions 
until 60 – 70 % confluency. Cells from 
passages 20 - 40 were used for the 
experiments.  
Evaluation of cytotoxicity  
 
The cytotoxic effects of the microparticles 
were investigated in Caco-2 cells by an 3-
(4,5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide (MTT) 
cytotoxicity assay [8]. The cells were seeded 
at a density 2 × 10
4
 cells/well in 96-well cell 
culture plates and pre-incubated for 24 h prior 
to microparticle treatment. The cells were 
then treated with the microparticles at various 
concentrations ranging from 0.01 to 0.5 
mg/ml in serum-free medium (pH 7.4) for 24 
h. After treatment, the microparticle 
suspensions were removed and fresh cell 
culture medium was added, and then 
incubated for 4 h to stabilize the cells. Finally, 
the cells were incubated with 100 µl MTT 
containing medium (0.1 mg/ml MTT in serum-
free medium) for 4 h; the medium was 
removed, and the formazan crystal formed in 
the living cells was dissolved in 100 µl DMSO 
per well. Relative cell viability (RCV) was 
calculated based on absorbance at 550 nm 
using a microplate reader (Universal 
Microplate Analyzer, model AOPUS01 and 
AI53601, Packard BioScience, CT, USA) 
using Eq 4. Viability of non-treated control 
cells was arbitrarily defined as 100 %. 
 
RCV = (OD550,sample – OD550,blank)/(OD550,control 
– OD550,blank) x 100 ……………….………  (4) 
 
Statistical analysis  
 
All experimental measurements were 
performed in triplicate and the data 
expressed as mean ± standard deviation 
(S.D.). Statistically significant differences 
were examined using one-way analysis of 
variance (ANOVA) followed by LSD post-hoc 
test. The level of significance was set at 
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Entrapment efficiency and allergen 
content of microparticles 
 
Table 1 shows the yield, entrapment 
efficiency and allergen content of Ag-CS-TPP 
microparticles. The yield obtained with this 
technique was in the range 34 - 76 % As the 
molecular weight (MW) of chitosan (CS) 
increased, allergen entrapment efficiency and 
content also increased. The highest allergen 
content (0.3 mg/g) was obtained for the 
microparticles containing 2.5 % Ag and CS 
MW of 460 kDa. Hence, this microparticle 
formulation was selected for alginate coating. 
 
Alginate-coated Ag-CS-TPP microparticles 
 
The lower the alginate solution concentration, 
the smaller the particles obtained. CaCl2 
concentration of 4 %w/v yielded 
microparticles with smaller size and more 
spherical shapes. Hence, the microparticles 
containing 0.025 %w/v alginate and 4 %w/v 
CaCl2 was selected for coating with alginate. 
The mean particle size of alginate-coated 
blank CS-TPP and Ag-CS-TPP microparticles 
were 14.88 ± 1.84 and 17.12 ± 2.04 µm, 
respectively. The surface charge of alginate 
coated CS-TPP and Ag-CS-TPP 
microparticles were -3.8 ± 2.2 and -7.2 ± 1.1 
mV, respectively. The negative charge was 
as a result of the alginate on the microparticle 
surface. TEM images (not shown) of the 
alginate-coated microparticles indicate that 
they were spherical. Entrapment efficiency 
and the allergen content of alginate-coated 
Ag-CS-TPP microparticles were 26±8.7 % 
and 0.3 mg/g particles, respectively.  
 
In vitro allergen release  
 
The release profile of allergen from the 
coated and uncoated Ag-CS-TPP 
microparticles is shown in Figure 1. Allergen 
release at pH 7.4 from alginate-coated Ag-
CS-TPP microparticles was approximately 95 
% over a period of 24 h, compared with about 
40 – 50 % at 24 h at pH 1.2. On the other 
hand, allergen release over a period of 24 h 
from the uncoated microparticles at pH 1.2 
was approx. 80 % which was higher than at 
pH 7.4 (65 %). In the case of alginate-coated 
CS-TPP microparticles, the higher allergen 












Figure 1:  In vitro release of allergen from Ag-CS-
TPP microparticles: in simulated gastric fluid (pH 
1.2, (■)); in PBS (pH 7.4, (▲)); alginate-coated Ag-
CS-TPP microparticles in simulated gastric fluid 
(pH 1.2, (□)); in PBS (pH 7.4, (∆)) 
 
Table 1: Yield, entrapment efficiency and allergen content of CS-TPP microparticles 
 




content (mg/g)  
0.1%Ag + CS 20 kDa 59.75 1.86±0.17 0.01±0.01 
0.5%Ag + CS 20 kDa 63.00 0.49±0.03 0.02±0.01 
2.5%Ag + CS 20 kDa 34.88 0.33±0.11 0.06±0.02 
0.1%Ag + CS 200 kDa 76.04 1.48±0.11 0.02±0.01 
0.5%Ag + CS 200 kDa 63.39 0.52±0.13 0.04±0.01 
2.5%Ag + CS 200 kDa 95.3 0.77±0.47 0.19±0.12 
0.1%Ag + CS 460 kDa 71.74 2.62±0.82 0.04±0.01 
0.5%Ag + CS 460 kDa 66.51 0.83±0.01 0.06±0.01 
2.5%Ag + CS 460 kDa 52.48 1.16±0.27 0.30±0.07 
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The cytotoxicity results, shown in Fig 2, 
indicate that after 24 h, there was no 
significant difference (p > 0.05) in viability 
between the cells treated with microparticles 
and untreated cells (control) at 
















Figure 2: Cell viability of micropaticles formulated 
with uncoated CS-TPP (plain bars) and alginate-
coated CS-TPP microparticles (striped bars) in 






Allergen entrapment in CS-TPP 
microparticles was most likely facilitated by 
electrostatic interaction of the positively-
charged (due to the amino group) chitosan 
and the negatively-charged allergen. The 
increase in entrapment efficiency with 
chitosan (CS) molecular weight (MW) has 
previously been reported [2,11,12] and may 
be due to the increase in CS solution 
viscosity with increase in MW which hinders 
the diffusion of the allergen from the droplet. 
The increase in the solution viscosity when 
higher chitosan concentration was used could 
be a major factor that influenced the rise in 
entrapment efficiency. Bazzo et al [12] who 
studied poly (3-hydroxybutyrate)/ 
chitosan/piroxicam and ketoprofen composite 
microparticles found that encapsulation 
efficiency decreased when chitosan 
concentration decreased. Increase in solution 
viscosity as chitosan concentration rose may 
account for the increase in entrapment 
efficiency of the microparticles. It has been 
claimed that enhancement of polymer 
solution viscosity elevated entrapment 
efficiency because it is more difficult for the 
drug to diffuse into the outer phase of the 
system [11].  
 
The spread length of chitosan chain in 
solution usually varies with MW, which could 
affect protein interaction and encapsulation. It 
has been found that bovine serum albumin 
(BSA) encapsulation efficiency increased 
from 61.1 to 69.9 and 78.2 % when the MW 
of chitosan was changed from low to medium 
and high, respectively [2]. This probably 
explains why the CS-TPP microparticles 
incorporating high MW CS showed the 
highest allergen content. 
 
The diameter of the beads formed using the 
electrostatic droplet technique would be 
dependent on the bore size of the needle 
used and the viscosity of the alginate 
solution. However, since needle bore size 
was not varied in this study, the viscosity of 
sodium alginate could also have influenced 
the diameter and shape of the beads 
produced. The beads became more spherical 
as the concentration of sodium alginate 




The allergen release from the microparticles 
can be partly attributed to the peculiar 
characteristics of chitosan. Chitosan 
dissolves easily at low pH while it is insoluble 
at higher pH ranges. The mechanism of the 
polymer’s pH-sensitive swelling involves the 
protonation of the amine groups of chitosan 
at low pH. This protonation leads to chain 
repulsion, diffusion of proton and counter ions 
along with water inside the gel and 
dissociation of secondary interactions. This 
produces the matrix that dissolves in the 
stomach. However, the higher allergen 
release from alginate-coated CS-TPP 
microparticles may be due to the fact that 
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at low pH but dissolves at high pH, and this 
explains the retardation of allergen release 
pH 1.2.  
 
Upon mixing, the carboxylate groups of 
alginate and the ammonium groups of 
chitosan ionically interact to form a 
polyelectrolyte complex. Complexation of 
alginate with chitosan reduces the porosity of 
the matrix and thus should decrease 
decrease the diffusion of the encapsulated 
material [14]. However, we found that higher 
allergen release from the alginate-coated 
microparticles actually occurred. And this 
might be due to the high affinity of phosphate 
ions to calcium ions. Therefore, when 
phosphate is present in the dissolution 
medium used, probable destabilizing of 
calcium-crosslinked alginate matrix by 
phosphate ions has to be taken into account 
as it may cause a faster opening or 
breakdown of crosslinking than in 0.1M HCl 
medium (pH 1.2) where such a phenomenon 
does not occur. Loss of calcium ions from the 
alginate coating resulted in increase of the 
permeability of the coating and consequently, 
increased diffusion of the allergen into the 
release medium [15]. 
 
Cytotoxicity of microparticles 
 
The findings of the present work correlate 
with results of another study which indicate 
that both alginate-coated and uncoated 
chitosan microparticles did not induce spleen 
cell death [15]. However, a recent study 
showed that CaCl2-crosslinked alginate 
microparticles caused a slight reduction in 
cell viability in human umbilical vein 
endothelial cells (HUVEC) cells except 





A suitable chitosan microparticles delivery 
system with sodium alginate coating yielded 
a formulation in the microsize range, and 
showing superior controlled allergen release 
property to the uncoated microparticles. The 
particles were non-toxic, thus indicating that 
alginate-coated chitosan microparticles were 
safe and can be further developed for 
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